ArticlePeerJ2018
Characterization and toxicity of citral incorporated with nanostructured lipid carrier.
Article in PeerJ, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- The Eco-Friendly Preparation of Se, Zn, and Ag MONPs and Their Current Medical Applications and Drug Delivery for AD Diseases.TheScientificWorldJournal · 2026Review
- Comparison of the effects of metformin, citral, Cymbopogon citratus extract and silver nanoparticles of Cymbopogon citratus extract on oxidative stress indices and Nrf2 levels in experimental type 2 diabetes in rats.Animal models and experimental medicine · 2025Article
- Citral and triclosan synergistically silence quorum sensing and potentiate antivirulence response in Pseudomonas aeruginosa.Archives of microbiology · 2024Article
- Bioactive Loaded Novel Nano-Formulations for Targeted Drug Delivery and Their Therapeutic Potential.Pharmaceutics · 2022Review
- Review
- Lemongrass Essential Oil Components with Antimicrobial and Anticancer Activities.Antioxidants (Basel, Switzerland) · 2021Review
- Recent Advances in Functional Polymer Materials for Energy, Water, and Biomedical Applications: A Review.Polymers · 2021Review
- In vitro effect of artemether-loaded nanostructured lipid carrier (NLC) onJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2021Article
- Artemether-loaded nanostructured lipid carriers: preparation, characterization, and evaluation ofResearch in pharmaceutical sciences · 2021Article
- Physicochemical characterization, cytotoxic effect and toxicity evaluation of nanostructured lipid carrier loaded with eucalyptol.BMC complementary medicine and therapies · 2021Article
- Development and Evaluation of 1'-Acetoxychavicol Acetate (ACA)-Loaded Nanostructured Lipid Carriers for Prostate Cancer Therapy.Pharmaceutics · 2021Article
- Ezetimibe-Loaded Nanostructured Lipid Carrier Based Formulation Ameliorates Hyperlipidaemia in an Experimental Model of High Fat Diet.Molecules (Basel, Switzerland) · 2021Article
- Nanotechnological strategies for systemic microbial infections treatment: A review.International journal of pharmaceutics · 2020Review
- Citral Protects Human Endothelial Cells Against Hydrogen Peroxide-induced Oxidative Stress.Turkish journal of pharmaceutical sciences · 2020Article
- Antitumor and Anti-Metastatic Effects of Citral-Loaded Nanostructured Lipid Carrier in 4T1-Induced Breast Cancer Mouse Model.Molecules (Basel, Switzerland) · 2020Article
- Terpenoids, Cannabimimetic Ligands, beyond theMolecules (Basel, Switzerland) · 2020Review
- Novel Drug Delivery Systems for Loading of Natural Plant Extracts and Their Biomedical Applications.International journal of nanomedicine · 2020Review
- Preparation and Characterization of Self Nano-Emulsifying Drug Delivery System Loaded with Citraland Its Antiproliferative Effect on Colorectal Cells In Vitro.Nanomaterials (Basel, Switzerland) · 2019Article
- In vitro cytotoxicity and anticancer effects of citral nanostructured lipid carrier on MDA MBA-231 human breast cancer cells.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The nanoparticle as a cancer drug delivery vehicle is rapidly under investigation due to its promising applicability as a novel drug delivery system for anticancer agents. This study describes the development, characterization and toxicity studies of a nanostructured lipid carrier (NLC) system for citral. Citral was loaded into the NLC using high pressure homogenization methods. The characterizations of NLC-citral were then determined through various methods. Based on Transmission Electron Microscope (TEM) analysis, NLC-Citral showed a spherical shape with an average diameter size of 54.12 ± 0.30 nm and a polydipersity index of 0.224 ± 0.005. The zeta potential of NLC-Citral was -12.73 ± 0.34 mV with an entrapment efficiency of 98.9 ± 0.124%, and drug loading of 9.84 ± 0.041%. Safety profile of the formulation was examined via
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.